Clinical Trial

Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus

Study acronym: LUMUS
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Protocol Amendment History 21 amendments
This ClinicalTrials.gov record has been amended 21 times since 2023-07-21; most recent amendment 2026-07-20.
Status change: Recruiting → Active, Not Recruiting 2025-07-30
Trial Details
NCT Number NCT05966480
Lead Sponsor Alumis Inc
Conditions SLE
Enrollment 408 participants
Start Date 2023-06-26
Primary Completion 2026-06-23 (estimated)
Study Completion 2027-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-21